Target intelligence / Profile preview

Poly(ADP-ribose) polymerase family member 16 (PARP16)

Target
PARP16
Molecular classification
Enzyme, ADP-ribosyltransferase, Poly(ADP-ribose) polymerase family
01

Overview

Poly(ADP-ribose) polymerase family member 16 (PARP16) is a tail-anchored, endoplasmic reticulum (ER)-associated enzyme that catalyzes the mono-ADP-ribosylation of target proteins, including critical ER stress sensors such as PERK and IRE1α, leading to their activation during the unfolded protein response (UPR)[1][2][4][5]. PARP16 also inhibits protein translation by ADP-ribosylating ribosomal subunits, and is implicated in regulating nucleocytoplasmic transport through modification of karyopherin-β1[1][2]. Additionally, PARP16 mono-ADP-ribosylates vascular endothelial growth factor (VEGF) in the ER, priming it for further modifications that modulate angiogenesis[1]. Recent evidence implicates PARP16 in maladaptive cardiac remodeling under conditions of pressure overload, suggesting relevance to cardiovascular disease[1]. PARP16 is classified as an enzyme within the ADP-ribosyltransferase and poly(ADP-ribose) polymerase family, with key roles in cellular stress responses, protein modification, translation regulation, and disease pathogenesis.

Other names
ARTD15pART15C15orf30PARP-16FLJ20509FLJ25281ADP-ribosyltransferase diphtheria toxin-like 15Protein mono-ADP-ribosyltransferase PARP16PART15PAR16_HUMAN
02

Mechanism of action

PARP16 inhibits protein translation by mono-ADP-ribosylating ribosomal proteins. It activates ER stress sensors like PERK and IRE1α through mono-ADP-ribosylation, thereby promoting the unfolded protein response. Additionally, it primes VEGF for further poly-ADP-ribosylation to modulate angiogenesis.

03

Biological functions

Unfolded protein responseProtein ADP-ribosylationRegulation of ER stress signalingRegulation of nucleocytoplasmic transportNegative regulation of protein translation
04

Disease associations

Cardiovascular disease (pathological cardiac hypertrophy, heart failure)Potential involvement in cancer and angiogenesis
05

Safety considerations

Potential impact on protein synthesis, ER stress homeostasis, and cardiac remodeling if modulated therapeutically

Beyond the preview

Go deeper on Poly(ADP-ribose) polymerase family member 16 (PARP16).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poly(ADP-ribose) polymerase family member 16 (PARP16).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call